Investor Alert

New York Markets Close in:

The Wall Street Journal Archives | Email alerts

Sept. 28, 2021, 3:20 a.m. EDT

Merck nears deal for rare-disease-drug maker Acceleron

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Merck & Co. Inc. (MRK)
  • X
    Acceleron Pharma Inc. (XLRN)
  • X
    Bristol Myers Squibb Co. (BMY)

or Cancel Already have a watchlist? Log In

By Cara Lombardo and Ben Dummett

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.

The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.

Should a deal come together, it would be one of Merck’s /zigman2/quotes/209956077/composite MRK -0.54% biggest and represent a bet on the treatments for the respiratory and blood diseases that Acceleron /zigman2/quotes/203395072/composite XLRN +0.02% specializes in.

Merck appears to have beaten out other potential suitors for Acceleron including Bristol Myers Squibb Co., /zigman2/quotes/202559280/composite BMY -2.95% which already owns a big stake in the company.

An expanded version of this story is available at WSJ.com

/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 81.81
-0.44 -0.54%
Volume: 4.01M
Oct. 27, 2021 1:34p
P/E Ratio
37.28
Dividend Yield
3.18%
Market Cap
$208.21 billion
Rev. per Employee
$648,824
loading...
/zigman2/quotes/203395072/composite
US : U.S.: Nasdaq
$ 173.81
+0.03 +0.02%
Volume: 270,982
Oct. 27, 2021 1:33p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$10.62 billion
Rev. per Employee
$296,548
loading...
/zigman2/quotes/202559280/composite
US : U.S.: NYSE
$ 56.52
-1.72 -2.95%
Volume: 10.44M
Oct. 27, 2021 1:33p
P/E Ratio
N/A
Dividend Yield
3.47%
Market Cap
$129.42 billion
Rev. per Employee
$1.41M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.